Researchers have created a urine test for prostate cancer that could make unnecessary biopsies a thing of the past. The high-performing diagnostic accurate | Clinical And Molecular Dx
Researchers have found that a new urine test is extremely accurate at detecting aggressive prostate cancer with few false negatives.
The test could have possibly avoided one third of unnecessary prostate cancer biopsies while failing to detect only a small number of cancers, according to a validation study of more than 1,500 patients.
The MyProstateScore test measures levels of cancer-specific genes in a patient’s urine. It’s based on previous research that discovered half of all prostate tumors harbor a certain genetic anomaly in which the genes TMPRSS2 and ERG relocate on a chromosome and fuse together creating an on-switch for prostate cancer development.
A urine test based on University of Michigan Rogel Cancer Center research could have avoided one third of unnecessary prostate cancer biopsies while failing to detect only a small number of cancers, according to a validation study that included more than 1,500 patients.
E-Mail
A urine test based on University of Michigan Rogel Cancer Center research could have avoided one third of unnecessary prostate cancer biopsies while failing to detect only a small number of cancers, according to a validation study that included more than 1,500 patients. The findings appear in the March issue of the
Journal of Urology.
The MyProstateScore test, which is being commercialized by LynxDX, a U-M startup company, measures levels of cancer-specific genes in a patient s urine. It is based on U-M research that discovered that half of all prostate tumors harbor a certain genetic anomaly in which the genes TMPRSS2 and ERG relocate on a chromosome and fuse together creating an on-switch for prostate cancer development.